| Literature DB >> 29431183 |
Sarah Watson1,2, Virginie Perrin1,2, Delphine Guillemot3, Stephanie Reynaud3, Jean-Michel Coindre4,5, Marie Karanian6, Jean-Marc Guinebretière7, Paul Freneaux8, François Le Loarer4,5, Megane Bouvet3, Louise Galmiche-Rolland9,10, Frédérique Larousserie11, Elisabeth Longchampt12, Dominique Ranchere-Vince6, Gaelle Pierron3, Olivier Delattre1,2,3,13, Franck Tirode1,2,14.
Abstract
Sarcoma represents a highly heterogeneous group of tumours. We report here the first unbiased and systematic search for gene fusions combined with unsupervised expression analysis of a series of 184 small round cell sarcomas. Fusion genes were detected in 59% of samples, with half of them being observed recurrently. We identified biologically homogeneous groups of tumours such as the CIC-fused (to DUX4, FOXO4 or NUTM1) and BCOR-rearranged (BCOR-CCNB3, BCOR-MAML3, ZC3H7B-BCOR, and BCOR internal duplication) tumour groups. VGLL2-fused tumours represented a more biologically and pathologically heterogeneous group. This study also refined the characteristics of some entities such as EWSR1-PATZ1 spindle cell sarcoma or FUS-NFATC2 bone tumours that are different from EWSR1-NFATC2 tumours and transcriptionally resemble CIC-fused tumour entities. We also describe a completely novel group of epithelioid and spindle-cell rhabdomyosarcomas characterized by EWSR1- or FUS-TFCP2 fusions. Finally, expression data identified some potentially new therapeutic targets or pathways.Entities:
Keywords: BCOR-rearranged; CIC-fused; EWSR1-PATZ1; FET-TFCP2; FUS-NFATC2; RNAseq; VGLL2-NCOA2; fusion genes; sarcoma
Mesh:
Substances:
Year: 2018 PMID: 29431183 DOI: 10.1002/path.5053
Source DB: PubMed Journal: J Pathol ISSN: 0022-3417 Impact factor: 7.996